NeuroPace (NASDAQ:NPCE) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of NeuroPace (NASDAQ:NPCE) to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

NPCE has been the subject of several other research reports. Leerink Partners reiterated an “outperform” rating and issued a $19.00 price objective on shares of NeuroPace in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research report on Monday, December 29th. HC Wainwright lifted their price target on shares of NeuroPace from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Wells Fargo & Company lifted their price target on shares of NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, UBS Group reiterated a “buy” rating on shares of NeuroPace in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, NeuroPace presently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

NeuroPace Stock Performance

Shares of NASDAQ NPCE opened at $14.03 on Wednesday. The company has a debt-to-equity ratio of 3.09, a current ratio of 5.28 and a quick ratio of 3.94. The firm has a market cap of $472.39 million, a price-to-earnings ratio of -21.26 and a beta of 1.86. The stock’s fifty day moving average price is $15.54 and its two-hundred day moving average price is $13.31. NeuroPace has a one year low of $7.56 and a one year high of $18.98.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The company had revenue of $26.59 million during the quarter, compared to the consensus estimate of $24.79 million. NeuroPace had a negative return on equity of 105.67% and a negative net margin of 21.47%. On average, equities analysts forecast that NeuroPace will post -1 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

Large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its position in shares of NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after buying an additional 1,118 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of NeuroPace by 86.0% during the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after acquiring an additional 1,239 shares during the period. GSA Capital Partners LLP boosted its position in shares of NeuroPace by 2.5% during the 3rd quarter. GSA Capital Partners LLP now owns 54,536 shares of the company’s stock worth $562,000 after acquiring an additional 1,323 shares in the last quarter. Quarry LP boosted its position in shares of NeuroPace by 94.9% during the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after acquiring an additional 1,872 shares in the last quarter. Finally, Man Group plc increased its stake in NeuroPace by 9.7% in the fourth quarter. Man Group plc now owns 21,626 shares of the company’s stock valued at $334,000 after acquiring an additional 1,920 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.